Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fantastic news and financially stable too. This FDA approval is enormously valuable in this opioid addicted world.
Sorry for your troubles - relief is on the way. Good luck with your shares.
Interesting options tell??? The $5.00 and $7.50 calls are suggesting
further upside volatility. In other words the FDA approval event did
not destroy the options value...the potential is there for an additional
upward move over time. Maybe the market expects a JV or BO announcement.
One could do well selling a covered out of the money call option here,
then repeat the process until eventually called away...sooner or later
this stock will be over $7.50...just a matter of time.
That’s how we did our DD on this one
Looks how beautiful it is.....so green......
Go $TRVN
jumped in when i saw the news feed about an hour ago......HUGE NEED......been in that position in hospitals many times.....if this pans out might get an old metal on metal hip replaced....suffer like an animal for 2 or 3 days, and the pricks won`t give any effective pain relief...... got in just under 3 bucks
$$$$$$$$$$$$$$$$$$$$$$ TREVENA $$$$$$$$$$$$$$$$$$$$$....gla
$TRVN PRE-MARKET WAS INVITING
$TRVN DATS AH WOW READ & INVESTMENT
Beautiful day today for this little biotech company
$TRVN Trevena Inc (TRVN)
3.11 ? 0.73 (30.67%)
Volume: 93,865,206 @08/10/20 2:41:31 PM EDT
Bid Ask Day's Range
3.1 3.11 2.86 - 3.68
TRVN Detailed Quote
Looks so good here
The odds of a $400M company getting FDA approval is very low. Adam Feurstein and a college professor have done research on the subject. You can google it.
Insiders probably sold before approval thinking the stock would go to $0.50 if the FDA came back with CRL.
Pfizer could acquire TRVN. Great post by Kev on why at the link below.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157471566
LMAO....old data before FDA approved
Why are insiders selling shares? What do they know that we dont.Hit 4.50 today and falling fast. Why would insiders be selling ?
https://ih.advfn.com/stock-market/NASDAQ/trevena-TRVN/stock-news/82751589/statement-of-changes-in-beneficial-ownership-4
Ten thousand $5 TRVN calls were sold today. The buyers of those calls believe TRVN will be higher than $5 by Aug 21st.
wow thats a beautiful thing..very nice ::)))
$TRVN bought 50,000 shares more at $2.86
whuups looks like to many people got caught in TRVN late. Lots of selling coming into the pump. Why did insiders sell ??? What do they know that is bad? I am adding 20,000 shares at $3.09
I did at $2.89....way to get it cheap down here before the run
Adding more at $2.92
$TRVN OLINVYK™ IS NOW FDA APPROVED
OLINVYK (oliceridine) injection is a new chemical entity indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
OLINVYK is not commercially available. Its controlled substance schedule is pending US Drug Enforcement Administration action.
https://olinvyk.com/
Not familiar
I like myocardia myok
Besides shorts covering, can anyone explain the drop after this great news. I've never seen a stock drop after FDA approval.
What do you think about omecamtiv (cardiac myosin activator) by Cytokinetics?
This is just the beginning
I was thinking when the shorts cover (directly after FDA approval) the pps would go up.
Well, I held this for less than 30 days...I guess I can hold it a bit more, lol.
I am adding 20,000 shares at $3.09
News: $TRVN Trevena Announces FDA Approval of OLINVYK(TM) (oliceridine) injection
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 Company funded through year-end 2021, including OLINVYK commercialization ...
In case you are interested TRVN - Trevena Announces FDA Approval of OLINVYK(TM) (oliceridine) injection
$TRVN huge reading peter
re;
$TRVN FDA approves Trevena's Olinvyk opioid for intravenous use in hospitals
Short is covering so we should be good later
WTF!!!! How is the pps falling AFTER approval?
Being held down so shorts can cover?? I don't know. Thought it would be running better than this. Or at least not dropping. Hmmmm...???
Is this really what longs thought they'd be waking up to? Friday night FOMO buyers are now bagholders. Happy with my early morning 4.40 short. Should do very well with it.
That's what I'm hoping for woohooooo TRVN$$$$$
Any concern here that we could see what transpired with ACRX last year? Market wanted to see sales and when that didn’t happen stock continued to drop?
In other words have we seen the high this morning until proof of sales or BO?
Awesome FDA announcement over the weekend and now wait for the conference call, this could easily to 12 dollars by end of the week or mid next week.
TRVN will now need to find a good partner like ZSAN which is in the same boat - PDUFA date is coming - so they found the partner ahead
TRVN $7 TARGET PRICE TODAY WOOHOOOOOOOOOO
Excellent. Enjoy your gains.
No worries bro. I am from nyc but live in Florida now. Enjoy your gains.
$TRVN FDA approves Trevena's Olinvyk opioid for intravenous use in hospitals
From RI...hopefully we will meet at some buyout party in the future...either TRVN or AMRN. I owe you drink, dinner... something.
7 million shares short. The SSR was activated on Friday. Short Sale Rule in effect through tomorrow's trading.
Almost 50% of their share were traded Friday during regular trading. Only 8 million AHs. Less in the last 30 minutes.
Could be a nice little short squeeze tomorrow. Good relationship with Pfizer. Pfizer could offer a 2:1 all stock deal and it would dilute them less than 1%. All speculation on my part. Pfizer 2:1 would be $19.22/share from Pfizer's Friday closing price.
Definitely a well positioned investment IMO...
KG ;)
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1330
|
Created
|
06/29/14
|
Type
|
Free
|
Moderators |
Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders.
The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.
The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.
Trevena is guided by an innovative spirit and an unwavering commitment to patients. It is a place driven by its employees – passionate and talented industry experts who operate with integrity, transparency, and respect for one another. Trevena employees are united in one mission: to deliver new medicines that address critical areas of need in CNS disorders.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |